Abstract
The purpose of the study was to evaluate the feasibility and safety of two cycles of high-dose chemotherapy (HDT) followed by autologous hematopoietic SCT (HSCT) in patients with poor prognosis Ewing family of tumors (EFT). Twenty patients with primary metastatic bulky disease or recurrent EFT were enrolled to a treatment protocol with two cycles of HDT and HSCT. Patients tolerated well the first (n=20) and second (n=13) cycles, with limited and predictable toxicities. Only one (5%) TRM occurred during the second cycle. Myeloid engraftment occurred at the median of 11 days after both cycles. At 3 years, the overall and EFS were 45% (confidence interval; CI 0.22, 0.69) and 47% (CI 0.25, 0.70), respectively, for the entire group and 58% (CI 0.30, 0.86) for patients who completed two cycles. Dose intensification with two cycles of HDT and HSCT is feasible and safe, with low and acceptable treatment-related morbidity and mortality. Adding a second course of therapy does not impair engraftment. However, only 65% of the patients were able to proceed to the second cycle. Further studies are required to define the optimal mode of delivery of HDT and HSCT in treatment of advanced EFT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18: 3108–3114.
Paulussen M, Ahrens S, Craft AW, Dunst J, Frohlich B, Jabar S et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 1998; 16: 3044–3052.
Cangir A, Vietti TJ, Gehan EA, Burgert Jr EO, Thomas P, Tefft M et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990; 66: 887–893.
Barker LM, Pendergrass TW, Sanders JE, Hawkins DS . Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 2005; 23: 4354–4362.
Frei III E, Canellos GP . Dose: a critical factor in cancer chemotherapy. Am J Med 1980; 69: 585–594.
Jurgens H, Exner U, Gadner H, Harms D, Michaelis J, Sauer R et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 1988; 61: 23–32.
Rosen G, Caparros B, Mosende C, McCormick B, Huvos AG, Marcove RC . Curability of Ewing's sarcoma and considerations for future therapeutic trials. Cancer 1978; 41: 888–899.
Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Forquer R, Wesley R et al. Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality therapy without maintenance. J Clin Oncol 1988; 6: 484–490.
Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348: 694–701.
Jaffe N, Paed D, Traggis D, Salian S, Cassady JR . Improved outlook for Ewing's sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. Cancer 1976; 38: 1925–1930.
Graham-Pole J, Lazarus HM, Herzig RH, Gross S, Coccia P, Weiner R et al. High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and Ewing's sarcoma. Am J Pediatr Hematol Oncol 1984; 6: 17–26.
Wexler LH, Delaney TF, Tsokos M, Avila N, Steinberg SM, Weaver-McClure L et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer 1996; 78: 901–911.
Craft A, Cotterill S, Malcolm A, Spooner D, Grimer R, Souhami R et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: the second United Kingdom children's cancer study group and the medical research council Ewing's tumor study. J Clin Oncol 1998; 16: 3628–3633.
Rosito P, Mancini AF, Rondelli R, Abate ME, Pession A, Bedei L et al. Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer 1999; 86: 421–428.
Bacci G, Picci P, Ferrari S, Mercuri M, Brach dP, Rosito P et al. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase—results of two sequential studies. Cancer 1998; 82: 1174–1183.
Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001; 19: 1818–1829.
Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide—a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004; 22: 2873–2876.
Burdach S, Jurgens H, Peters C, Nurnberger W, Mauz-Korholz C, Korholz D et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993; 11: 1482–1488.
Miser JS, Kinsella TJ, Triche TJ, Steis R, Tsokos M, Wesley R et al. Treatment of peripheral neuroepithelioma in children and young adults. J Clin Oncol 1987; 5: 1752–1758.
Horowitz ME, Kinsella TJ, Wexler LH, Belasco J, Triche T, Tsokos M et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993; 11: 1911–1918.
Ladenstein R, Hartmann O, Pinkerton CR . The role of megatherapy with autologous bone marrow rescue in solid tumours of childhood. Ann Oncol 1993; 4 (Suppl 1): 45–58.
Cornbleet MA, Corringham RE, Prentice HG, Boesen EM, McElwain TJ . Treatment of Ewing's sarcoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Treat Rep 1981; 65: 241–244.
Atra A, Whelan JS, Calvagna V, Shankar AG, Ashley S, Shepherd V et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant 1997; 20: 843–846.
Pinkerton CR . Intensive chemotherapy with stem cell support-experience in pediatric solid tumours. Bull Cancer 1995; 82 (Suppl 1): 61s–65s.
Burdach S, Meyer-Bahlburg A, Laws HJ, Haase R, van Kaik B, Metzner B et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 2003; 21: 3072–3078.
Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, Defor TE, Baker KS et al. Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors. Bone Marrow Transplant 2006; 37: 175–181.
Meyers PA, Krailo MD, Ladanyi M, Chan KW, Sailer SL, Dickman PS et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001; 19: 2812–2820.
Gratwohl A, Baldomero H, Demirer T, Rosti G, Dini G, Ladenstein R et al. Hematopoietic stem cell transplantation for solid tumors in Europe. Ann Oncol 2004; 15: 653–660.
Michon J, Hartmann O, Demeocq F, Brunat-Mentigny M, Coze C, Boutard P et al. Consolidation with busulfan and melphalan following by blood progenitor cell (BPC) graft in children and young adults with high risk Ewing's Sarcoma: a report of the French Society of Pediatric Oncology (abstract). J Clin Oncol 1994; 13: A1415.
Diaz MA, Vicent MG, Madero L . High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Bone Marrow Transplant 1999; 24: 1157–1159.
Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Societe Francaise des Cancers de l’Enfant. J Clin Oncol 2006; 24: 3997–4002.
Jurgens H, Exner U, Kuhl J, Ritter J, Treuner J, Weinel P et al. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma. Cancer Chemother Pharmacol 1989; 24 (Suppl 1): S40–S44.
Grupp SA, Stern JW, Bunin N, Nancarrow C, Adams R, Gorlin JB et al. Rapid-sequence tandem transplant for children with high-risk neuroblastoma. Med Pediatr Oncol 2000; 35: 696–700.
Adams RH, Smith L, Grier HE . Rapid sequence tandem transplants for children with metastatic sarcoma. Biol Blood Marrow Transplant 2001; 7: 64 (abstract 1).
Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M . Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. Pediatr Blood Cancer 2007; 49: 196–198.
Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 2002; 20: 2284–2292.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rosenthal, J., Bolotin, E., Shakhnovits, M. et al. High-dose therapy with hematopoietic stem cell rescue in patients with poor prognosis Ewing family tumors. Bone Marrow Transplant 42, 311–318 (2008). https://doi.org/10.1038/bmt.2008.169
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.169
Keywords
This article is cited by
-
Ewing Sarcoma Drug Therapy: Current Standard of Care and Emerging Agents
Pediatric Drugs (2023)
-
Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults
Bone Marrow Transplantation (2015)
-
Efficacy of carbon-ion radiotherapy and high-dose chemotherapy for patients with unresectable Ewing’s sarcoma family of tumors
International Journal of Clinical Oncology (2013)
-
Autologous stem cell transplantation in adults with metastatic sarcoma of the Ewing family: a single centre experience
Wiener klinische Wochenschrift (2013)
-
Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment
Clinical Sarcoma Research (2012)